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Mutational spectrum and
phenotypic variability of
VCP-related neurological
disease in the UK
INTRODUCTION
Hereditary inclusion body myopathy
(IBM) with Paget’s disease of the bone
(PDB) and frontotemporal dementia
(FTD) (IBMPFD) is a rare autosomal dom-
inant disorder due to mutations in the
valosin-containing protein gene (VCP).1
Pathogenic VCP variants have also been
associated with amyotrophic lateral scler-
osis2 and other phenotypes including
dilated cardiomyopathy and Parkinson’s
disease. We describe phenotypic and
genetic ﬁndings of 42 individuals from 21
families with VCP mutations. As our
service is the reference laboratory for the
UK, we calculated the UK’s point preva-
lence based on the 2011 Census as the
number of cases per population.
RESULTS
In total, 42 individuals were identiﬁed, 23
men and 19 women from 21 kinships (see
online supplementary tables S1A, B).
Based on our data, the expected point
prevalence of IBMPFD in the UK is
0.066/100 000 population.
Eighteen unrelated patients harbour a
previously described mutation. In addition,
three patients from two families harbour
two novel variants (c.604G>T, p.G202W
in exon 6 and c.1316C>G, p.A439G in
exon 11) that are predicted to be patho-
genic by in silico analysis (Alamut interpret-
ation software V.2.4) and segregate with
disease. Three previously described
mutations were identiﬁed in exon 5 of the
VCP gene. The mutation p.R155H
(c.464G>A) was found in 11 families. The
mutation p.R191Q (c.572G>A) was found
in three unrelated patients, p.R155C
(c.463C>T) in two families, and p.R93C
(c.277C>T) in two unrelated patients (see
online supplementary material genetic ana-
lysis and mutation analysis).
The mean age of disease onset was
42.05±7.94 years. Three individuals were
tested as part of a family screening and
were asymptomatic at the ages of 21, 23
and 31 years.
Muscle weakness was the ﬁrst manifest-
ation (ﬁgure 1) in 92.3% of patients, PDB
was the ﬁrst symptom in one case, and in
two cases we were unable to obtain this
information. Proximal weakness of both
limb girdles was the presentation in 27%
of patients; 21.6% presented with prox-
imal upper limb weakness, and 13.5%
with proximal lower limb weakness. A
combination of distal and/or proximal
upper and/or lower limb weakness at
onset was seen in 24.2%. In two patients,
falls were the ﬁrst reported symptom.
Twenty-three patients remained ambu-
lant after 15.7±8.2 years (range 5–39).
The mean time to loss of ambulation was
13.37±6.6 years (range 5–22 years). Of
the 10 non-ambulant patients, 6 (60%)
experienced some degree of cognitive
decline compared with 33.3% of the
ambulant patients.
Additional clinical ﬁndings (see online
supplementary table S2) were scapular
winging in 20 patients (50%), markedly
atrophic hands in 6 patients (15.4%), camp-
tocormia, or bent spine, in 6 (15.4%),
ﬁnger extensor weakness in 5 (12.8%),
facial weakness in 3 (7.7%) and weakness
of abdominal muscles in two patients
(5.1%). An asymmetric pattern of muscle
involvement was present in nine patients
(23%). Nine patients (23%) experienced
sphincter or erectile dysfunction. Two
patients were diagnosed with rheumatoid
arthritis and two with Parkinson’s disease.
Back pain (4 patients), cramps and muscle
pain (12 patients) were frequently reported.
Forced vital capacity systematically
assessed in 20 patients, was reduced in 2,
requiring non-invasive ventilation after,
respectively, 16 and 18 years of disease
duration. ECG was performed in 14
patients. Three patients from the same
family had moderate left ventricular dys-
function, 10, 11 and 17 years after the
ﬁrst symptoms. For the last patient, there
was a past history of myocardial infarct
(MCI). Severe progressive FTD or MCI
was observed in 14 of 29 patients
(48.2%); in 5 patients, data were not
available. PDB was conﬁrmed in eight
patients, and ﬁve other reported bone
pain. In three cases, despite normal
X-rays, bone alkaline phosphatase serum
levels were high.
Serum creatine kinase (CK) levels were
measured in 19 of 40 patients. In 13 patients
(68.4%), CK levels were mildly raised with a
mean value of 379.6±142.1 U/L (N=0–
150), and a range between 162 and 725 U/
L. Neurophysiological data were available
for 19 of 39 patients. Myopathic changes
were reported in 10 of these patients, 5 pre-
sented a neurogenic pattern and 4 patients, a
mixed myopathic and neurogenic pattern.
Muscle biopsies, available for 17 patients,
showed mild, unspeciﬁc myopathic changes
except for 1, which showed a dystrophic
pattern. Eleven biopsies (61%) revealed
rimmed vacuoles.
Figure 1 Patient 6 illustrates a pseudo-FSHD pattern. Note the scapular involvement (A) and pronounced scapular winging (B). Patient 21: note
the wasting of the forearm and thenar eminence (C). Muscle MRI of pelvic girdle (D), thigh (E) and lower leg (F), showing mild fatty inﬁltration of
Gluteus, more pronounced fatty inﬁltration of vastus lateralis, vastus medialis, adductor magnus and sartorius.
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DISCUSSION
At present, only 43 families with VCP
mutations have been reported worldwide
to the Leiden Open Variation Database
(LVOD). Our data indicate a point preva-
lence of IBMPFD of 0.066/100 000 for the
UK population as a whole. Although we
accept that these ﬁgures need to be inter-
preted with caution, and cases may remain
unrecognised, they suggest that IBMPFD is
a very rare disease. As our department is a
specialised service for muscle diseases, it is
not surprising that muscle weakness was
the ﬁrst symptom in the majority of
patients; with either a limb-girdle or com-
bined proximal-distal distribution. Distal
weakness, mostly affecting the small hand
muscles, generally an extremely rare pres-
entation of myopathy, was identiﬁed in
several patients with IBMPFD.
Approximately half of our patients
remained ambulant after 17.8±7.5 years.
Dementia, or MCI, seems to correlate
with the severity of the disease, as 60% of
our patients with dementia or MCI were
non-ambulant, compared with 33.3% of
the patients without cognitive decline.
This data on rate of progression is similar
to previous reports.3
By comparison, the number of patients
with respiratory or cardiac insufﬁciency
was relatively low. They constitute the
main cause of death in IBMPFD,3 and
should be regularly monitored.
The presence of sphincter and erectile
dysfunction, and of Parkinson’s disease,
further expands the phenotypic character-
istics of IBMPFD. Parkinson’s disease has
recently been recognised as a clinical
manifestation of VCP-related disease.3 4
The presence of rimmed vacuoles,
although non-speciﬁc, remains the major
histological hallmark of IBMPFD.
The identiﬁcation of mutations in differ-
ent exons emphasises that full gene
sequencing is required to exclude
VCP-related disease. Owing to multisystem
involvement, this disease should perhaps
be called VCP-related disease to try to
encompass the muscle, bone and central
nervous system manifestations.
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